Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LCL004
MIFTS: 38

Localized Osteosarcoma

Categories: Bone diseases, Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Localized Osteosarcoma

About this section

MalaCards integrated aliases for Localized Osteosarcoma:

Name: Localized Osteosarcoma 11 14 71
Localised Osteogenic Sarcoma 11
Localized Osteogenic Sarcoma 11
Localised Osteosarcoma 11

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:3356
NCIt 49 C7780
UMLS 71 C0278511
Sources

Summaries for Localized Osteosarcoma

About this section

MalaCards based summary: Localized Osteosarcoma, also known as localised osteogenic sarcoma, is related to osteogenic sarcoma and childhood osteosarcoma. An important gene associated with Localized Osteosarcoma is FAM87B (Family With Sequence Similarity 87 Member B), and among its related pathways/superpathways are Signal Transduction and Akt Signaling. The drugs Cisplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are Decreased viability and Increased cell viability after pRB stimulation
Sources

Related Diseases for Localized Osteosarcoma

About this section

Diseases related to Localized Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 osteogenic sarcoma 30.6 TP53 TNFSF11 IGF1R AKT1
2 childhood osteosarcoma 29.6 TP53 EWSR1 ERBB2 AKT1
3 leukemia, acute myeloid 28.2 TP53 PDGFRB IGF1R EWSR1 ERBB2 CD274
4 apocrine adenosis of breast 10.2 TP53 ERBB2
5 parotid gland cancer 10.2 TP53 ERBB2
6 pericytoma with t(7;12) 10.2 EWSR1 ACTB
7 gestational ovarian choriocarcinoma 10.2 TP53 ERBB2
8 breast metaplastic carcinoma 10.2 TP53 ERBB2
9 comedo carcinoma 10.2 TP53 ERBB2
10 pleomorphic adenoma carcinoma 10.2 TP53 ERBB2
11 breast sarcoma 10.2 TP53 ERBB2
12 breast malignant phyllodes tumor 10.2 TP53 ERBB2
13 apocrine adenocarcinoma 10.2 TP53 ERBB2
14 ovarian carcinosarcoma 10.2 TP53 ERBB2
15 intraductal breast benign neoplasm 10.2 TP53 ERBB2
16 synchronous bilateral breast carcinoma 10.2 TP53 ERBB2
17 rhabdoid cancer 10.2 TP53 IGF1R EWSR1
18 bone giant cell sarcoma 10.1 TP53 TNFSF11
19 lung oat cell carcinoma 10.1 TP53 AKT1
20 esophageal adenosquamous carcinoma 10.1 TP53 ERBB2
21 lung carcinoma in situ 10.1 TP53 AKT1
22 sweat gland disease 10.1 TP53 EWSR1 ERBB2
23 salivary gland disease 10.1 TP53 EWSR1 ERBB2
24 penile benign neoplasm 10.1 TP53 CD274
25 pleomorphic carcinoma 10.1 TP53 CD274
26 salivary gland carcinoma 10.1 TP53 EWSR1 ERBB2
27 mixed oligodendroglioma-astrocytoma 10.1 TP53 CD274
28 central nervous system primitive neuroectodermal neoplasm 10.1 TP53 EWSR1
29 lymphoepithelioma-like carcinoma 10.1 TP53 CD274
30 gallbladder adenocarcinoma 10.1 TP53 ERBB2
31 brain glioblastoma multiforme 10.1 TP53 AKT1
32 breast juvenile papillomatosis 10.1 ERBB2 AKT1
33 carbuncle 10.1 AKT1 ACTB
34 anal squamous cell carcinoma 10.1 TP53 CD274
35 bone benign neoplasm 10.0 TP53 TNFSF11 EWSR1
36 bone squamous cell carcinoma 10.0 TP53 CD274
37 neurofibromatosis, type i 10.0 TP53 EWSR1 AKT1
38 myxofibrosarcoma 10.0 TP53 EWSR1 CD274
39 papilloma 10.0 TP53 ERBB2 AKT1
40 hypertrophy of breast 10.0 TP53 ERBB2 AKT1
41 female reproductive endometrioid cancer 10.0 TP53 ERBB2 AKT1
42 bone sarcoma 10.0 TP53 EWSR1 AKT1
43 dedifferentiated liposarcoma 10.0 TP53 EWSR1 CD274
44 estrogen-receptor negative breast cancer 10.0 TP53 ERBB2 AKT1
45 breast lobular carcinoma 10.0 TP53 ERBB2 AKT1
46 adrenal carcinoma 10.0 TP53 IGF1R AKT1
47 skin squamous cell carcinoma 10.0 TP53 ERBB2 AKT1
48 breast carcinoma in situ 10.0 TP53 ERBB2 AKT1
49 serous cystadenocarcinoma 10.0 TP53 ERBB2 AKT1
50 ductal carcinoma in situ 10.0 TP53 ERBB2 AKT1

Graphical network of the top 20 diseases related to Localized Osteosarcoma:



Diseases related to Localized Osteosarcoma
Sources

Symptoms & Phenotypes for Localized Osteosarcoma

About this section

GenomeRNAi Phenotypes related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.89 AKT1 IGF1R PDGFRB
2 Decreased viability GR00221-A-2 9.89 AKT1 IGF1R
3 Decreased viability GR00221-A-3 9.89 AKT1 ERBB2 IGF1R PDGFRB
4 Decreased viability GR00221-A-4 9.89 AKT1 ERBB2 PDGFRB
5 Decreased viability GR00249-S 9.89 AKT1
6 Decreased viability GR00301-A 9.89 IGF1R
7 Decreased viability GR00342-S-1 9.89 PDGFRB
8 Decreased viability GR00342-S-2 9.89 IGF1R
9 Decreased viability GR00402-S-2 9.89 IGF1R
10 Increased cell viability after pRB stimulation GR00230-A-1 8.8 AKT1 ERBB2 IGF1R

MGI Mouse Phenotypes related to Localized Osteosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.01 ACTB AKT1 ERBB2 EWSR1 FRZB PDGFRB
2 behavior/neurological MP:0005386 10 ACTB AKT1 CD274 ERBB2 EWSR1 FRZB
3 neoplasm MP:0002006 9.98 ACTB AKT1 ERBB2 EWSR1 IGF1R TNFSF11
4 muscle MP:0005369 9.97 ACTB AKT1 ERBB2 EWSR1 IGF1R PDGFRB
5 limbs/digits/tail MP:0005371 9.87 ERBB2 EWSR1 FRZB IGF1R PDGFRB TNFSF11
6 reproductive system MP:0005389 9.81 ACTB AKT1 ERBB2 EWSR1 IGF1R KHDRBS3
7 skeleton MP:0005390 9.61 AKT1 CD274 ERBB2 EWSR1 FRZB IGF1R
8 integument MP:0010771 9.28 AKT1 CD274 ERBB2 EWSR1 FRZB IGF1R
Sources

Drugs & Therapeutics for Localized Osteosarcoma

About this section

Drugs for Localized Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
5
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
7
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
10
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
12
Palifosfamide Investigational Phase 3 31645-39-3 100427
13 Antirheumatic Agents Phase 3
14 Folic Acid Antagonists Phase 3
15 Antiviral Agents Phase 3
16 Folate Phase 3
17 Anti-Bacterial Agents Phase 3
18 Alkylating Agents Phase 3
19 Interferon alpha-2 Phase 3
20 Antineoplastic Agents, Alkylating Phase 3
21 Anti-Infective Agents Phase 3
22 Vitamin B9 Phase 3
23
Etoposide phosphate Phase 3 16760419
24 Antimitotic Agents Phase 3
25 Keratolytic Agents Phase 3
26 interferons Phase 3
27 Vitamin B Complex Phase 3
28 Interferon-alpha Phase 3
29 Interferon-alfa-1b Phase 3
30 Antimetabolites Phase 3
31 Tubulin Modulators Phase 3
32 Antibiotics, Antitubercular Phase 3
33 Liposomal doxorubicin Phase 3
34 Immunosuppressive Agents Phase 3
35 Dermatologic Agents Phase 3
36 Immunologic Factors Phase 3
37
Mifamurtide Approved, Experimental 83461-56-7 21891368
38
Thromboplastin

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy Unknown status NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
2 Retrospective Study of Genetic Risk Factors for Osteosarcoma Completed NCT00954473
3 Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma Completed NCT01190943
4 Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma Completed NCT01374672
5 Observational - Tissue Factor Expression in Bone Sarcomas Completed NCT01807052
6 Localized Osteosarcoma of Extremities: Developing a Clinical Prediction Model From a Country With Limited Resources Completed NCT03839095
7 Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study Recruiting NCT03737435
8 Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma Active, not recruiting NCT04890067

Search NIH Clinical Center for Localized Osteosarcoma

Sources

Genetic Tests for Localized Osteosarcoma

About this section
Sources

Anatomical Context for Localized Osteosarcoma

About this section

Organs/tissues related to Localized Osteosarcoma:

MalaCards : Bone, Lung, T Cells, Endothelial, Kidney, Heart, Brain
Sources

Publications for Localized Osteosarcoma

About this section

Articles related to Localized Osteosarcoma:

(show top 50) (show all 143)
# Title Authors PMID Year
1
First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. 62
36469563 2022
2
Limb salvage surgery has a higher complication rate than amputation but is still beneficial for patients younger than 10 years old with osteosarcoma of an extremity. 62
35490054 2022
3
Fatal heart disease in patients with bone and soft tissue sarcoma. 62
36312272 2022
4
Bone Infarct-Associated Osteosarcoma: Epidemiologic and Survival Trends. 62
35034028 2022
5
Cryoablation-aided joint retention surgery for epiphysis involvement in osteosarcoma compared with endoprosthetic replacement. 62
34334045 2021
6
The prognostic significance of lymphovascular tumor invasion in localized high-grade osteosarcoma: Outcomes of a single institution over 10 years. 62
33621357 2021
7
The relation between staging fluorine-18 fluorodeoxyglucose positron emission tomog- raphy/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patients 62
33387988 2021
8
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis. 62
33948428 2021
9
Clinical significance of indeterminate pulmonary nodules on the survival of 364 patients with nonmetastatic, high-grade, localized osteosarcoma: A 12-year retrospective cohort study. 62
33289124 2021
10
Exosomes as Efficient Nanocarriers in Osteosarcoma: Biological Functions and Potential Clinical Applications. 62
34712664 2021
11
The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. 62
33469302 2021
12
Radiological Assessment and Outcome of Local Disease Progression after Neoadjuvant Chemotherapy in Children and Adolescents with Localized Osteosarcoma. 62
33348627 2020
13
Prognostic factors in High-Grade Localized Osteosarcoma of the Extremities: The Tunisian Experience. 62
33283661 2020
14
Maintenance therapy and drug holiday in sarcoma patients: systematic review. 62
32400254 2020
15
CORR Insights®: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 62
31977429 2020
16
CORR® Tumor Board: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 62
32118597 2020
17
Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. 62
32475245 2020
18
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? 62
31904683 2020
19
Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation. 62
32444660 2020
20
Engineering 2D Mesoporous [email protected] 3D-Printing Scaffolds for Combinatory Osteosarcoma Therapy and NO-Augmented Bone Regeneration. 62
32108432 2020
21
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt. 62
31107367 2020
22
Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps. 62
32300279 2020
23
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. 62
32483726 2020
24
Therapeutic Potential of Circular RNAs in Osteosarcoma. 62
32351876 2020
25
Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma. 62
31667064 2019
26
Osteosarcoma and second malignant neoplasms: a case series. 62
31054046 2019
27
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. 62
30629005 2019
28
Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy? 62
30859285 2019
29
Osteosarcoma after the age of fifty: A clinicopathological study. 62
31014986 2019
30
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma. 62
31024791 2019
31
Malignant Bone Tumors of the Knee: How to Identify and Treat. 62
30449025 2019
32
MiR-204-5p promotes apoptosis and inhibits migration of osteosarcoma via targeting EBF2. 62
30529043 2019
33
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. 62
30304898 2019
34
Crosstalk between Hh and Wnt signaling promotes osteosarcoma progression. 62
31933884 2019
35
Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study. 62
31187043 2019
36
The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. 62
30193198 2018
37
Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. 62
30241221 2018
38
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. 62
30131550 2018
39
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. 62
29592877 2018
40
Current and future therapeutic approaches for osteosarcoma. 62
29210294 2018
41
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. 62
29340095 2017
42
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. 62
28631382 2017
43
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. 62
27918348 2017
44
p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. 62
27544803 2016
45
Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. 62
27457945 2016
46
Risk-Based Therapy for Localized Osteosarcoma. 62
26501936 2016
47
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. 62
26381138 2015
48
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. 62
26304877 2015
49
Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies. 62
25231396 2015
50
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. 62
26175892 2015
Sources

Variations for Localized Osteosarcoma

About this section
Sources

Expression for Localized Osteosarcoma

About this section
Search GEO for disease gene expression data for Localized Osteosarcoma.
Sources

Pathways for Localized Osteosarcoma

About this section

Pathways related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.61 TP53 PDGFRB KHDRBS3 IGF1R ERBB2 CD274
2
Akt Signaling 64
Show member pathways
 13.2 TP53 TNFSF11 PDGFRB IGF1R ERBB2 AKT1
3
PAK Pathway 64
Show member pathways
 13.13 TNFSF11 PDGFRB IGF1R ERBB2 AKT1 ACTB
4
Phospholipase-C Pathway 64
Show member pathways
 12.93 TP53 PDGFRB IGF1R AKT1 ACTB
5
TNFR1 Pathway 64
Show member pathways
 12.77 TP53 TNFSF11 IGF1R AKT1 ACTB
6
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.69 PDGFRB IGF1R ERBB2 AKT1 ACTB
7
fMLP Pathway 64
Show member pathways
 12.63 TP53 IGF1R AKT1 ACTB
8
Signaling by Receptor Tyrosine Kinases 66
12.6 ACTB AKT1 CD274 ERBB2 IGF1R PDGFRB
9
Endometrial cancer 74
Show member pathways
 12.57 TP53 IGF1R ERBB2 AKT1
10
Immune response IL-23 signaling pathway 22
Show member pathways
 12.43 TP53 PDGFRB ERBB2 AKT1
11
Malignant pleural mesothelioma 74
12.24 TP53 PDGFRB IGF1R CD274 AKT1 ACTB
12
NF-kappaB Pathway 70
Show member pathways
 12.18 TP53 PDGFRB IGF1R ERBB2 AKT1
13
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.15 PDGFRB IGF1R ERBB2 AKT1
14
MAPK Signaling: Mitogens 65
Show member pathways
 12.02 TP53 PDGFRB IGF1R ERBB2 AKT1
15
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.99 IGF1R ERBB2 AKT1
16
Focal adhesion 74
11.95 PDGFRB IGF1R ERBB2 AKT1 ACTB
17
Ebola virus infection in host 74
11.92 IGF1R AKT1 ACTB
18
Endochondral ossification 74
Show member pathways
 11.9 IGF1R FRZB AKT1
19
MAPK Pathway 70
Show member pathways
 11.88 TP53 ERBB2 AKT1
20
Development EGFR signaling via small GTPases 22
Show member pathways
 11.83 AKT1 ERBB2 PDGFRB
21
mTOR Pathway 70
Show member pathways
 11.64 TP53 IGF1R AKT1
22
Burn wound healing 74
11.6 AKT1 PDGFRB TP53
23
Breast cancer pathway 74
Show member pathways
 11.53 TP53 TNFSF11 PDGFRB IGF1R ERBB2 AKT1
24
Pathways affected in adenoid cystic carcinoma 74
11.5 TP53 ERBB2 AKT1
25
mTOR Signaling 65
11.5 TP53 PDGFRB IGF1R ERBB2 AKT1
26
Head and neck squamous cell carcinoma 74
11.49 TP53 IGF1R ERBB2 AKT1
27
Hepatitis C and hepatocellular carcinoma 74
11.41 TP53 FRZB AKT1
28
Alzheimers Disease Pathway 64
11.29 PDGFRB IGF1R ERBB2
29
S1P3 pathway 61
10.79 PDGFRB AKT1
30
Caloric restriction and aging 74
10.53 TP53 AKT1
31
Somatroph axis (GH) and its relationship to dietary restriction and aging 74
10.18 IGF1R AKT1
Sources

GO Terms for Localized Osteosarcoma

About this section

Biological processes related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.76 PDGFRB IGF1R ERBB2 AKT1
2 response to fluid shear stress GO:0034405 9.56 PDGFRB AKT1
3 multicellular organism development GO:0007275 9.5 PDGFRB IGF1R ERBB2
4 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 PDGFRB IGF1R AKT1
5 phosphatidylinositol 3-kinase signaling GO:0014065 9.1 IGF1R ERBB2 AKT1

Molecular functions related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 PDGFRB IGF1R ERBB2
Sources

Sources for Localized Osteosarcoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....